Open toolbar PROFESSIONAL INVESTMENTS PENSIONS ABOUT US NEWS CONTACT PAYMENT FORM Investors Support Could Revolutionise Fracture Treatment Funding for the development and launch of an innovative new medical device which could revolutionise the treatment of broken bones is being driven by Wilton Corporate Finance Limited. Funding for the development and launch of an innovative new medical device which could revolutionise the treatment of broken bones is being driven by Wilton Corporate Finance Limited. Wilton is managing the opportunity to invest into Cambridge Orthopaedic Labs (COL) as part of a £3.5m Enterprise Investment Scheme (“EIS”) eligible fundraising round, for a 38.7% stake in the business. COL has developed a non-invasive external fixator (“PolyArmour”) of great potential to improve patient experience and outcomes as well as being cost effective and affordable for healthcare providers when compared to traditional, invasive procedures. Led by an experienced, orthopaedic specialist management team, COL has published clinical trial results which support PolyArmour’s efficacy, while management estimates PolyArmour will be able to treat around two thirds of the estimated 18 million fractures which occur globally each year. Senior figures at Wilton are backing the COL team. James Robson, Head of Financial Services at Wilton, explained: ‘During our discussions with the team at Cambridge Orthopaedic Labs, we were impressed with the world class combination of medical and commercial orthopaedic specialists and it quickly became clear to us that this was an initiative worthy of investment.’ Wilton Head of Corporate Finance, Paul Osbourn added that ‘while there is risk in any early stage investment, we believe that in PolyArmour, COL has developed a product that has already demonstrated that it can improve patient outcomes and do so via a treatment that patients and healthcare providers will both in general prefer. This is why we believe COL has a real chance of making an impact on a multi billion dollar annual global fracture treatment market.’ Wilton Managing Partner Tony Flanagan concluded that ‘people will always break bones and trauma patient treatments cannot be deferred. By reducing the need for invasive surgical treatments, PolyArmour can also help alleviate hospital capacity constraints. At Wilton we are happy to help innovative firms by offering them strategic and operational support. We believe investors will consider an attractive opportunity to finance at an early stage a business with tremendous potential and to help bring a valuable new product to market.’ To find out more, or to invest, access the virtual data room, which includes the investment teaser, IM and subscription agreement, or email CorporateFinance@wiltongroup.com. WOULD YOU LIKE TO KNOW MORE? If you feel your business could benefit from our knowledge and expertise, use the form below to contact us and one of our experts will be in touch. Check here if you accept our terms (Privacy Policy) PROFESSIONAL | INVESTMENTS | PENSIONS LONDON | ISLE OF MAN | IRELAND | DUBAI | BRISTOL | BLACKBURN London +44 (0)20 7355 3525 | IOM +44 (0)1624 675610 | Ireland +353 (0)1 405 4882 | Dubai +971 (0)4 441 0518 | Bristol +44 (0)117 316 9991 | Blackburn +44 (0)125 466 0333 mail@wiltongroup.com Privacy Policy | Terms & Conditions | Covid-19 Secure Risk Assessment | Covid-19 Update © 2020 The Wilton Group, Website design by bob